Köthe Andreas, Feuvret Loïc, Weber Damien Charles, Safai Sairos, Lomax Antony John, Fattori Giovanni
Center for Proton Therapy, Paul Scherrer Institute, 5232 Villigen, Switzerland.
Department of Physics, ETH Zürich, 8093 Zürich, Switzerland.
Cancers (Basel). 2021 Oct 23;13(21):5327. doi: 10.3390/cancers13215327.
Radiation-induced optic neuropathy (RION) is a rare side effect following radiation therapy involving the optic structures whose onset is, due to the low amount of available data, challenging to predict. We have analyzed a multi-institutional cohort including 289 skull-base cancer patients treated with proton therapy who all received >45 Gy to the optic apparatus. An overall incidence rate of 4.2% (12) was observed, with chordoma patients being at higher risk (5.8%) than chondrosarcoma patients (3.2%). Older age and arterial hypertension, tumor involvement, and repeated surgeries (>3) were found to be associated with RION. Based on bootstrapping and cross-validation, a NTCP model based on age and hypertension was determined to be the most robust, showing good classification ability (AUC-ROC 0.77) and calibration on our dataset. We suggest the application of this model with a threshold of 6% to segment patients into low and high-risk groups before treatment planning. However, further data and external validation are warranted before clinical application.
放射性视神经病变(RION)是涉及视神经结构的放射治疗后一种罕见的副作用,由于可用数据量少,其发病难以预测。我们分析了一个多机构队列,包括289例接受质子治疗的颅底癌患者,他们对视神经装置的照射剂量均>45 Gy。观察到总体发病率为4.2%(12例),脊索瘤患者的风险(5.8%)高于软骨肉瘤患者(3.2%)。发现年龄较大、动脉高血压、肿瘤累及以及多次手术(>3次)与RION相关。基于自举法和交叉验证,确定基于年龄和高血压的NTCP模型最为稳健,在我们的数据集中显示出良好的分类能力(AUC-ROC为0.77)和校准效果。我们建议在治疗计划前应用该模型,以6%为阈值将患者分为低风险和高风险组。然而,在临床应用前需要进一步的数据和外部验证。